Michael Thomas Heffernan Sells 25,000 Shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) Stock

Share on StockTwits

Collegium Pharmaceutical Inc (NASDAQ:COLL) Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $11.26, for a total transaction of $281,500.00. Following the sale, the director now directly owns 132,069 shares of the company’s stock, valued at approximately $1,487,096.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Thomas Heffernan also recently made the following trade(s):

  • On Monday, June 17th, Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $11.37, for a total transaction of $284,250.00.
  • On Wednesday, May 15th, Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $12.84, for a total transaction of $321,000.00.

Shares of COLL opened at $10.53 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.24 and a debt-to-equity ratio of 0.22. Collegium Pharmaceutical Inc has a 12-month low of $10.41 and a 12-month high of $21.20. The firm has a 50-day moving average price of $12.06.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.01. Collegium Pharmaceutical had a negative net margin of 10.36% and a negative return on equity of 30.87%. The firm had revenue of $74.52 million during the quarter, compared to analyst estimates of $70.10 million. Equities research analysts anticipate that Collegium Pharmaceutical Inc will post -0.44 EPS for the current year.

COLL has been the subject of a number of research reports. Janney Montgomery Scott initiated coverage on shares of PLx Pharma in a report on Friday, April 12th. They set a “buy” rating for the company. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. BidaskClub lowered shares of Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research lowered shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Ballard Power Systems in a report on Friday, May 3rd. Three analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $26.17.

Institutional investors and hedge funds have recently made changes to their positions in the stock. MERIAN GLOBAL INVESTORS UK Ltd purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $26,000. First Quadrant L P CA purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $36,000. BNP Paribas Arbitrage SA grew its holdings in shares of Collegium Pharmaceutical by 67,855.6% in the first quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock valued at $93,000 after purchasing an additional 6,107 shares during the period. Oregon Public Employees Retirement Fund purchased a new position in Collegium Pharmaceutical during the fourth quarter worth about $103,000. Finally, Virginia Retirement Systems ET AL purchased a new position in Collegium Pharmaceutical during the first quarter worth about $160,000. 94.83% of the stock is owned by hedge funds and other institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: What does it mean to hold a stock in street name?

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Western Midstream Partners  Downgraded by LADENBURG THALM/SH SH
Western Midstream Partners Downgraded by LADENBURG THALM/SH SH
Zoetis  Given New $130.00 Price Target at SunTrust Banks
Zoetis Given New $130.00 Price Target at SunTrust Banks
UDR  Price Target Raised to $52.00
UDR Price Target Raised to $52.00
SunTrust Banks Lowers Twin River Worldwide  Price Target to $24.00
SunTrust Banks Lowers Twin River Worldwide Price Target to $24.00
Zions Bancorporation NA  Downgraded by BidaskClub
Zions Bancorporation NA Downgraded by BidaskClub
Peel Hunt Reaffirms Hold Rating for Admiral Group
Peel Hunt Reaffirms Hold Rating for Admiral Group


© 2006-2019 Ticker Report